| 3.04 -0.13 (-4.1%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.78  |
1-year : | 4.31 |
| Resists | First : | 3.23 |
Second : | 3.69 |
| Pivot price | 3.08  |
|||
| Supports | First : | 2.5 |
Second : | 2.07 |
| MAs | MA(5) : | 3.33 |
MA(20) : | 2.99 |
| MA(100) : | 4.34 |
MA(250) : | 7.36 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.8 |
D(3) : | 71.9 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 12.06 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVH ] has closed above bottom band by 46.2%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.39 - 3.42 | 3.42 - 3.43 |
| Low: | 3.09 - 3.12 | 3.12 - 3.14 |
| Close: | 3.14 - 3.17 | 3.17 - 3.2 |
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Sat, 07 Mar 2026
Precision Trading with Evolent Health Inc Class A (EVH) Risk Zones - Stock Traders Daily
Mon, 02 Mar 2026
Cowen Maintains Buy on Evolent Health (EVH) March 2026, PT Cut to $7 - Meyka
Thu, 26 Feb 2026
Hear Evolent execs at March Cowen and Oppenheimer investor conferences - Stock Titan
Thu, 26 Feb 2026
Evolent Health: Cheap, Levered, But Ready To Rebound (NYSE:EVH) - Seeking Alpha
Wed, 25 Feb 2026
Evolent Health: Q4 Earnings Snapshot - cbs19news.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 112 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 110.3 (%) |
| Shares Short | 20,210 (K) |
| Shares Short P.Month | 19,130 (K) |
| EPS | -5.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.72 |
| Profit Margin | -28.5 % |
| Operating Margin | -2.1 % |
| Return on Assets (ttm) | -0.2 % |
| Return on Equity (ttm) | -66.6 % |
| Qtrly Rev. Growth | -27.5 % |
| Gross Profit (p.s.) | 3.58 |
| Sales Per Share | 16.83 |
| EBITDA (p.s.) | 0.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 39 (M) |
| Levered Free Cash Flow | 98 (M) |
| PE Ratio | -0.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 0.18 |
| Price to Cash Flow | 8.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|